Alumis Inc. ALMS
$22.17
▲ +15.55% 24H
About
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and exp…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees225
TickerALMS
Statistics
Market Cap$2.82B
Revenue (TTM)$24.1M
Net Income-$243.3M
Net Margin-1011.7%
EPS$-1.78
P/E0.17
P/S309.85
P/B4.58
EV/EBITDA-4.74
ROE-64.6%
Dividend Yield—
Price$22.17
Data: Twelve Data · Revenue = mcap / P/S